 |
 |
The study to me suggests that I should not jump to any conclusion,...yet. Inasmuch as Comtan is NOT the therapeutic medication but Sinemet is, one would have to think of what and how Comtan affects the activity of Sinemet, and that I would think is the primary role of this drug. In the absence of contrary evidence, I would suggest that Comtan increases the efficacy of Sinemet so that the time window between doses is increased resulting in lessening the frequency of dosage thus a reduction of total Sinemet intake. Any supporters? Michel Margosis 'Carpe Diem' Benjamin Winter wrote: > "The plasma elimination half-life of [entacapone] is 1.5 to > 3.5 hours." -- Statement quoted from RIVEST J et al. COMT > inhibitors in Parkinson’s disease. Can J Neurol Sci 1999; > Suppl 2, Aug 1999: S34-S38 -- apparently based on NUTT JG et > al. in Neurology 1994; 44:913-919. > > Similar information comes from KERANEN T et al [in Eur J > Clin Pharmacol 1994;46(2):151-7], as follows: > > "... an open study in 12 healthy young male volunteers ... > Entacapone was rapidly eliminated by metabolism with a > half-life of 0.27-0.30 h after oral doses of 5 to 50 mg. > After doses from 100 to 800 mg the disposition was best > described by two phases with a t1/2 alpha of 0.27-0.37 h and > t1/2 beta of 1.59-3.44 h." > > To me this suggests that, in general, a person taking Comtan > once daily would have the benefit of the drug for part - but > not all - of the day. > > Ben Winter > Victoria BC Canada